Sino Biopharmaceutical Ltd banner

Sino Biopharmaceutical Ltd
HKEX:1177

Watchlist Manager
Sino Biopharmaceutical Ltd Logo
Sino Biopharmaceutical Ltd
HKEX:1177
Watchlist
Price: 6.33 HKD -0.47% Market Closed
Market Cap: HK$118.8B

Multiples-Based Value

The Multiples-Based Value of one Sino Biopharmaceutical Ltd stock under the Base Case scenario is 3.78 HKD. Compared to the current market price of 6.33 HKD, Sino Biopharmaceutical Ltd is Overvalued by 40%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Multiples-Based Value
Base Case
3.78 HKD
Overvaluation 40%
Multiples-Based Value
Price HK$6.33
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Sino Biopharmaceutical Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
Sino Biopharmaceutical Ltd
HKEX:1177
113.3B HKD 3.1 42.7 12.9 12.9
US
Eli Lilly and Co
NYSE:LLY
883.9B USD 13.6 42.8 28.9 30.8
US
Johnson & Johnson
NYSE:JNJ
585.2B USD 6.2 21.8 15.2 18.6
UK
AstraZeneca PLC
LSE:AZN
237.5B GBP 5.4 31.2 17.2 24.2
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.7 11.6 13.1
US
Merck & Co Inc
NYSE:MRK
299.1B USD 4.6 16.4 10.1 12.3
CH
Novartis AG
SIX:NOVN
236.4B CHF 5.4 21.8 13.5 17.3
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.6 9
US
Pfizer Inc
NYSE:PFE
161B USD 2.6 20.7 7.9 10.5
US
Bristol-Myers Squibb Co
NYSE:BMY
120B USD 2.5 17 7.2 8.8
P/E Multiple
Earnings Growth PEG
HK
Sino Biopharmaceutical Ltd
HKEX:1177
Average P/E: 24.4
42.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.8
7%
3.1
UK
AstraZeneca PLC
LSE:AZN
31.2
26%
1.2
CH
Roche Holding AG
SIX:ROG
19.7
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.4
14%
1.2
CH
Novartis AG
SIX:NOVN
21.8
14%
1.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
20.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
Sino Biopharmaceutical Ltd
HKEX:1177
Average EV/EBITDA: 46.1
12.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.9
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
UK
AstraZeneca PLC
LSE:AZN
17.2
13%
1.3
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
CH
Novartis AG
SIX:NOVN
13.5
5%
2.7
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Pfizer Inc
NYSE:PFE
7.9
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
Sino Biopharmaceutical Ltd
HKEX:1177
Average EV/EBIT: 99.9
12.9
18%
0.7
US
Eli Lilly and Co
NYSE:LLY
30.8
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.6
6%
3.1
UK
AstraZeneca PLC
LSE:AZN
24.2
21%
1.2
CH
Roche Holding AG
SIX:ROG
13.1
6%
2.2
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2.1
CH
Novartis AG
SIX:NOVN
17.3
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
US
Pfizer Inc
NYSE:PFE
10.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett